Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Blood (2019) 134 (Supplement_1): 3965.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals